Combination measles, mumps, rubella and varicella vaccine.

摘要: A comparative clinical trial was conducted in 15- to 17-month-old healthy children compare an investigational combination measles, mumps, rubella, varicella (MMRV) vaccine v standard rubella followed 6 weeks later with the (MMR + V) vaccine. Both MMRV and MMR V schedules stimulated virtually 100% seroconversion for all component viruses. Mean antibody titers were similar each virus two groups. Clinical reactivity postimmunization also 25% 29% morbilliform rashes, 12% mild papulovesicular (varicella) 12.5% 18% temperature elevations above 38.3 degrees C (101 F). Antibodies viruses persistent at 1 year of follow-up both Varicella 8/10 originally seronegative vaccinees 5/5 recipients tested. One recipient had a household exposure chickenpox during postvaccination that resulted subclinical boost titer. Two group close exposures; (20 lesions) developed one. There no known exposures natural or rubella. Three four low titer prior immunization greater than fourfold increases antibodies after vaccination. The is immunogenic, safe, cost-effective approach children. Continued work needed select appropriate dose component, assure higher persistence rate antibody.